Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial

By sjmartinez • December 16, 2022

Waters M, McKinnell JA, Kalil AC, Martin GS, Buchman TG, Theess W, Yang X, Lekkerkerker AN, Staton T, Rosenberger CM, Pappu R, Wang Y, Zhang W, Brooks L, Cheung D, Galanter J, Chen H, Mohan D, Peck MC; COVID-astegolimab-interleukin (IL) (COVASTIL) Study Group. Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial. Crit Care Med. 2023 Jan 1;51(1):103-116. doi: 10.1097/CCM.0000000000005716. Epub 2022 Nov 14. PMID: 36519984.

Tags: Infectious Diseases, Publications

Accelerating CEST MRI With Deep Learning-Based Frequency Selection and Parameter Estimation

Shen C, Cheema K, Xie Y, Ruan D, Li D. Accelerating CEST MRI With Deep Learning-Based Frequency Selection and Parameter Estimation. NMR Biomed. 2025 Jul;38(7):e70068.[...]

Sustainability and spread of best practices for peri-operative antimicrobial stewardship following discontinuation of mandatory public reporting: perceptions from the Society for Healthcare Epidemiology in America research network

Pendergast J, Mull H, Shin M, Engle R, Elwy AR, Strymish J, Golenbock S, Hederstedt K, Ostrow R, Goetz MB, Hawn M, Branch-Elliman W. Sustainability[...]

Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy

Lu MT, Ribaudo HJ, McCallum S, Zanni MV, deFilippi C, Taron J, Karady J, Foldyna B, Paradis K, Chu SM, Diggs MR, Burdo TH, Currier[...]